CDG Biotech is Poised to Enter the Market for Diagnostic Assay Solutions in the Fight Against Allergies and Rare Diseases

Dec 01, 2016 Mark

Press Release (ePRNews.com) - Westlake Village, CA - Dec 01, 2016 - CDG Biotech announced today that it has secured FDA Registration and was granted a Device Manufacturing License from the State of California Department of Public Health, Food, and Drug Branch.

“CDG Biotech develops diagnostic assays for the detection of allergies and esoteric-rare diseases. As an established Biotech company new to California, we have achieved the first major milestone of our business plan ahead of schedule. Within 10 months we have completed the build up of our infrastructure and facilities. With this registration and licensure we are now fully operational and we are well positioned to provide enhanced diagnostic services to healthcare professionals around the world,” CEO, Noel A. Silva

About CDG Biotech:

CDG Biotech offers customized biomedical technology solutions that meet strict requirements of quality while improving efficiency, effectiveness and results. With International headquarters in Venezuela and now its domestic offices and laboratory located in Westlake Village, CA, CDG Biotech will begin development, manufacturing, and worldwide sales and distribution of specialized products to the global biomedical community.

Contact: www.cdgbiotech.com

Source : CDG Biotech Corp Follow on Google News
Business Info :
CDG Biotech Corp
31332 Via Colinas Suite 111
Westlake Village, CA 91362
Phone: 8052220877
Website: http://www.cdgbiotech.com
SHARE :  

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login

DISCLAIMER

If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.